JP2023541671A5 - - Google Patents

Info

Publication number
JP2023541671A5
JP2023541671A5 JP2023517699A JP2023517699A JP2023541671A5 JP 2023541671 A5 JP2023541671 A5 JP 2023541671A5 JP 2023517699 A JP2023517699 A JP 2023517699A JP 2023517699 A JP2023517699 A JP 2023517699A JP 2023541671 A5 JP2023541671 A5 JP 2023541671A5
Authority
JP
Japan
Prior art keywords
composition according
seq
immunotherapy composition
item
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541671A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045055 external-priority patent/WO2022060487A1/en
Publication of JP2023541671A publication Critical patent/JP2023541671A/ja
Publication of JP2023541671A5 publication Critical patent/JP2023541671A5/ja
Pending legal-status Critical Current

Links

JP2023517699A 2020-09-17 2021-08-06 シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン Pending JP2023541671A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079819P 2020-09-17 2020-09-17
US63/079,819 2020-09-17
PCT/US2021/045055 WO2022060487A1 (en) 2020-09-17 2021-08-06 Alpha-synuclein vaccine for the treatment of synucleinopathies

Publications (2)

Publication Number Publication Date
JP2023541671A JP2023541671A (ja) 2023-10-03
JP2023541671A5 true JP2023541671A5 (enExample) 2024-08-14

Family

ID=80777122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517699A Pending JP2023541671A (ja) 2020-09-17 2021-08-06 シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン

Country Status (12)

Country Link
US (1) US20230355756A1 (enExample)
EP (1) EP4213867A4 (enExample)
JP (1) JP2023541671A (enExample)
KR (1) KR20230087487A (enExample)
CN (1) CN116783211A (enExample)
AR (1) AR123189A1 (enExample)
AU (1) AU2021344230A1 (enExample)
CA (1) CA3192429A1 (enExample)
IL (1) IL301224A (enExample)
MX (1) MX2023003007A (enExample)
TW (1) TW202227465A (enExample)
WO (1) WO2022060487A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan
CN121358786A (zh) 2023-06-15 2026-01-16 3M创新有限公司 底胶组合物、粘合剂体系和相关方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
HUE043966T2 (hu) * 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
PL2583978T3 (pl) * 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
EP2772267B1 (en) * 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
AU2013344571A1 (en) * 2012-11-16 2015-06-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Gonorrheal MtrE peptides and vaccines
CA3051839A1 (en) * 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3638298A4 (en) * 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA
WO2019070480A1 (en) * 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES
CN111787942B (zh) * 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
AU2019275072A1 (en) * 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens

Similar Documents

Publication Publication Date Title
JP2023526500A5 (enExample)
JP2023541669A5 (enExample)
JP2023541670A5 (enExample)
JP2023541671A5 (enExample)
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
JP2023536995A5 (enExample)
US9095536B2 (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
JP2023536746A5 (enExample)
TWI252233B (en) Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
KR20080097188A (ko) 항아밀로이드 면역성성분, 그 제조방법 및 용도
US9163062B2 (en) Albumin-amyloid peptide conjugates and uses thereof
US20030175285A1 (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
US20230287050A1 (en) Immunogenic Compounds
KR20240147981A (ko) 항-알파시누클레인 치료 백신
US20080175871A1 (en) Eliciting improved immune responses
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
JP2024538615A5 (enExample)
EA048154B1 (ru) Иммуногенные соединения
RU2021103287A (ru) Самособирающийся пептидный каркас
HK1169831A (en) A beta immunogenic peptide carrier conjugates and methods of producing same
HK1171460A (en) Beta immunogenic peptide carrier conjugates and methods of producing the same